Long-Term Debt and Other Financings - Novartis Note (Details) - USD ($) $ in Thousands |
1 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|
Oct. 20, 2021 |
Oct. 21, 2020 |
Jun. 30, 2021 |
Mar. 31, 2005 |
Dec. 31, 2021 |
Dec. 31, 2020 |
Dec. 31, 2017 |
Dec. 31, 2015 |
Sep. 30, 2015 |
|
| Long-term debt | |||||||||
| Revenue from contracts with customers | $ 36,518 | $ 27,941 | |||||||
| Loss on extinguishment of debt | (300) | ||||||||
| Novartis Note | |||||||||
| Long-term debt | |||||||||
| Research and development expenses funded through loan facility, maximum (as a percent) | 75.00% | ||||||||
| Maximum borrowing capacity under loan agreement | $ 50,000 | ||||||||
| Repayments of debt | $ 9,100 | ||||||||
| Amount by which note will be reduced upon achievement of specified milestones | $ 25,000 | $ 7,300 | |||||||
| Reduction in debt obligation | 7,300 | ||||||||
| Debt amount | 0 | 9,100 | |||||||
| Novartis Note | Six-month LIBOR | |||||||||
| Long-term debt | |||||||||
| Basis spread on variable rate | 2.00% | ||||||||
| Novartis International | License Agreement | |||||||||
| Long-term debt | |||||||||
| Revenue from contracts with customers | $ 35,000 | 25,000 | $ 35,000 | $ 25,000 | $ 10,000 | $ 37,000 | |||
| Cash payment received | $ 17,700 | $ 37,000 | |||||||
| X | ||||||||||
- Definition Percentage points added to the reference rate to compute the variable rate on the debt instrument. No definition available.
|
| X | ||||||||||
- Definition Net increase or decrease in the carrying amount of the debt instrument for the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The maximum percentage of aggregate costs of clinical research and development expenses that are funded through a debt instrument under collaborative arrangements and are not incurred by the Company. No definition available.
|
| X | ||||||||||
- Definition The amount by which the note will be reduced upon achievement of specified milestones rather than receiving cash payment under the terms of the agreement. No definition available.
|
| X | ||||||||||
- Definition Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|